MSD (known as Merck in the United States) and Moderna have reported positive results from a Phase III clinical trial of their mRNA based cancer vaccine for melanoma. According to the original report from Clinical Trials Arena, the companies now plan to use the data to seek regulatory approval for the treatment, bringing the experimental vaccine closer to the market.

Key takeaways

  • The Phase III trial tested the mRNA cancer vaccine (mRNA-4157/V940) in combination with MSD’s immunotherapy Keytruda (pembrolizumab) in patients with high risk melanoma.
  • Results showed a statistically significant improvement in recurrence free survival compared to Keytruda alone.
  • MSD and Moderna intend to submit the findings to health authorities in the coming months to begin the approval process.
  • If approved, this would be the first mRNA cancer vaccine to reach the market, building on the technology used in Moderna’s COVID 19 vaccine.

What is the MSD Moderna cancer vaccine?

The vaccine, known as mRNA-4157 (V940), is an individualized neoantigen therapy. It is designed to train the immune system to recognize and attack specific mutations in a patient’s own tumor cells. Unlike traditional vaccines that prevent infectious diseases, this is a therapeutic vaccine meant to treat existing cancer and reduce the risk of recurrence.

Moderna contributes the mRNA platform, while MSD supplies Keytruda, a checkpoint inhibitor that helps T cells stay active against cancer. The combination aims to prime the immune system with the vaccine and then remove the brakes with Keytruda.

How did the Phase III trial work?

The Phase III trial enrolled patients with completely resected, high risk melanoma. After surgery, patients were randomly assigned to receive either the vaccine plus Keytruda or Keytruda alone. The primary endpoint was recurrence free survival, meaning how long patients lived without the cancer coming back.

According to the original report, the trial met its primary endpoint, showing a clear benefit for the combination. The companies have not yet released the full data, but they described the results as positive and statistically significant.

What do the results mean for patients?

For people with high risk melanoma, the possibility of a personalized vaccine that lowers the chance of recurrence represents a major step forward. Currently, standard treatment after surgery is often observation or immunotherapy alone, but many patients still experience relapse. If approved, the vaccine could offer a new option to improve outcomes.

The trial results also signal that mRNA technology, which proved effective against COVID 19, can be adapted for cancer treatment. This could open the door to similar vaccines for other tumor types in the future.

What are the next steps?

MSD and Moderna plan to present the full data at an upcoming medical conference and to submit the results to regulators, including the U.S. Food and Drug Administration and the European Medicines Agency. The companies have not specified a timeline for submission, but the goal is to begin the approval process as soon as possible.

If regulators grant approval, the vaccine would become the first mRNA cancer vaccine to enter the market. The companies have already begun manufacturing scale up to prepare for potential launch.

Frequently Asked Questions

Who is eligible for this cancer vaccine?

Based on the Phase III trial, the vaccine is being studied in patients with high risk melanoma that has been completely removed by surgery. The eligibility criteria may expand if further trials are conducted in other cancer types or stages.

How is the vaccine personalized?

Each patient’s tumor is genetically sequenced to identify unique mutations. Moderna then creates a custom mRNA vaccine that encodes up to 34 neoantigens. This personalized approach means no two patients receive exactly the same vaccine.

When could the vaccine become available?

If the regulatory submission proceeds smoothly, the vaccine could gain approval within the next year or two. However, the timeline depends on the completeness of the data and the speed of review by health authorities. The companies have not given a specific launch date.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.